InsidersTradesSigma
Follow the XENON PHARMACEUTICALS INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €6bn. The latest transaction was reported on 28 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: CHRISTOPHER KENNEY. Every trade is free.
Analysts rate XENON PHARMACEUTICALS INC Strong Buy (bullish), based on 19 analysts. Average price target: US$81.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Xenon Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for rare genetic diseases. It utilizes its drug discovery platform to identify and develop innovative therapies.